Trial Profile
Clinical Course of Treatment With ESBRIET in Patients With Mild to Moderate IPF
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2017
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Roche
- 26 Feb 2017 Status changed from recruiting to completed.
- 09 Dec 2015 New trial record